Acute Respiratory Distress Syndrome Epidemiology Forecast till 2030

September 10 14:55 2020
Acute Respiratory Distress Syndrome Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Acute Respiratory Distress Syndrome Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology Perspective by DelveInsight

The Acute Respiratory Distress Syndrome (ARDS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Acute Respiratory Distress Syndrome (ARDS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Acute Respiratory Distress Syndrome (ARDS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

ARDS Epidemiology Segmentation in 7MM from 2017 to 2030

  • Total Incident Population of ARDS
  • Severity-specific Incidence of ARDS
  • Incidence of ARDS by Risk Factors

ARDS Epidemiology Insights

  • The total incident population of ARDS in 7MM in 2017 was 7,99,872
  • The incidence of ARDS in the United States in 2017 was 4, 95,655 

Request for sample pages
Table of contents

1. Key Insights 

2. Executive Summary of Acute Respiratory Distress Syndrome (ARDS)

3. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Acute Respiratory Distress Syndrome (ARDS) Treatment and Management

6.2. Acute Respiratory Distress Syndrome (ARDS) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/